Parvovirus B19 IgM and IgG

Product Description

IDS Parvovirus B19 IgG or IgM is an automated in-vitro diagnostics device intended for the semi-quantitative determination of specific IgG or IgM class antibodies directed against the Parvovirus B19 in human serum or plasma samples on the IDS system. Results are to be used for assessing the parvovirus B19 antibody status in individuals who may be at risk of infection from, or who have been infected with, parvovirus B19.

Appropriate patient management, IgM and IgG results from same sample tube

• Screening patients for B19V antibody status will determine the need for further follow-up.
• An IgG-positive, IgM-negative pregnant women should be reassured that B19V infection is not a cause for concern during their pregnancy.

Confidence in the results

• Selected recombinant VP2 antigen for optimal test performance
• Traceable to the WHO IS 01/602 for IgG, with results express in IU/mL.
• No observed cross-reactivity with common viruses such as EBV, VZV and CMV

Streamlined workflow, rapid results and cost effective

• Ready to use, 50 tests reagents cartridge with up to 60 days on-board storage.
• Calibrate once every 21 days with common controls for both IgM and IgG assays
• Suitable for use with serum or plasma (sodium heparin, sodium citrate, potassium EDTA) samples.